-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Kiniksa Pharmaceuticals, Maintains $34 Price Target

Benzinga·04/16/2025 14:06:15
Listen to the news
Wedbush analyst David Nierengarten reiterates Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and maintains $34 price target.